• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy.

作者信息

Sethi Supreet, Kumar Sanjeev, Lim Kathlyn, Jordan Stanley C

机构信息

Department of Medicine, Division of Nephrology, Cedars Sinai Medical Center, Los Angeles, California, USA.

出版信息

Kidney Int Rep. 2020 Jul 3;5(9):1515-1518. doi: 10.1016/j.ekir.2020.06.030. eCollection 2020 Sep.

DOI:10.1016/j.ekir.2020.06.030
PMID:32954076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7486170/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e937/7486170/9f093fa1940a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e937/7486170/f37064b8a8f6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e937/7486170/9f093fa1940a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e937/7486170/f37064b8a8f6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e937/7486170/9f093fa1940a/gr2.jpg

相似文献

1
Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy.奥妥珠单抗对难治性膜性肾病有效。
Kidney Int Rep. 2020 Jul 3;5(9):1515-1518. doi: 10.1016/j.ekir.2020.06.030. eCollection 2020 Sep.
2
Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.利妥昔单抗治疗巴基斯坦人群难治性特发性膜性肾病
J Ayub Med Coll Abbottabad. 2019 Apr-Jun;31(2):265-268.
3
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.奥妥珠单抗联合来那度胺治疗复发或难治性滤泡性B细胞淋巴瘤（GALEN）：一项多中心、单臂、2期研究。
Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8.
4
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.奥滨尤妥珠单抗联合苯达莫司汀对比苯达莫司汀单药治疗利妥昔单抗难治性惰性非霍奇金淋巴瘤（GADOLIN）：一项随机、对照、开放标签、多中心、3 期临床试验。
Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23.
5
Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy.利妥昔单抗治疗难治性同时性抗肾小球基底膜（抗GBM）病和膜性肾病。
Clin Kidney J. 2014 Feb;7(1):53-6. doi: 10.1093/ckj/sft152. Epub 2014 Jan 12.
6
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.在 IIIb 期 GREEN 研究中，奥滨尤妥珠单抗单药或联合化疗治疗未经治疗或复发/难治性慢性淋巴细胞白血病的安全性。
Haematologica. 2018 Nov;103(11):1889-1898. doi: 10.3324/haematol.2017.186387. Epub 2018 Jul 5.
7
Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.奥妥珠单抗：利妥昔单抗难治或复发滤泡性淋巴瘤的综述
Target Oncol. 2017 Apr;12(2):255-262. doi: 10.1007/s11523-017-0485-6.
8
Obinutuzumab for the treatment of indolent lymphoma.奥妥珠单抗用于惰性淋巴瘤的治疗。
Future Oncol. 2016 Aug;12(15):1769-81. doi: 10.2217/fon-2016-0084. Epub 2016 Apr 27.
9
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.阿伐度胺联合奥滨尤妥珠单抗治疗复发或难治性B细胞非霍奇金淋巴瘤患者（CC-122-NHL-001）：一项多中心、剂量递增及扩展的1期研究。
Lancet Haematol. 2020 Sep;7(9):e649-e659. doi: 10.1016/S2352-3026(20)30208-8. Epub 2020 Aug 3.
10
A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.低剂量氟达拉滨治疗难治性膜性肾病的一项初步研究。
Clin Nephrol. 1999 Aug;52(2):67-75.

引用本文的文献

1
Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study.奥妥珠单抗治疗原发性膜性肾病的疗效与安全性：一项真实世界回顾性研究。
Front Immunol. 2025 Aug 21;16:1650054. doi: 10.3389/fimmu.2025.1650054. eCollection 2025.
2
Identification of early predictors of clinical remission in primary membranous nephropathy: a analysis of the STARMEN trial.原发性膜性肾病临床缓解的早期预测因素识别：STARMEN试验分析
Clin Kidney J. 2025 Aug 13;18(9):sfaf256. doi: 10.1093/ckj/sfaf256. eCollection 2025 Sep.
3
Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial.

本文引用的文献

1
Successful Treatment of Patients With Refractory PLAR-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases.奥滨尤妥珠单抗成功治疗难治性 PLAR 相关膜性肾病 3 例报告。
Am J Kidney Dis. 2020 Dec;76(6):883-888. doi: 10.1053/j.ajkd.2020.02.444. Epub 2020 Apr 18.
2
Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.利妥昔单抗治疗膜性肾病中中和抗利妥昔单抗抗体与复发的关系。
Front Immunol. 2020 Jan 13;10:3069. doi: 10.3389/fimmu.2019.03069. eCollection 2019.
3
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
奥妥珠单抗作为磷脂酶A2受体相关原发性膜性肾病的初始治疗有效：一项回顾性单中心试验
Drug Des Devel Ther. 2025 Jul 11;19:5961-5972. doi: 10.2147/DDDT.S527661. eCollection 2025.
4
Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy.添加奥滨尤妥珠单抗在利妥昔单抗难治性膜性肾病中实现高缓解率。
Am J Nephrol. 2025 May 19:1-9. doi: 10.1159/000545995.
5
Obinutuzumab as a Promising Treatment for Membranous Nephropathy.奥妥珠单抗作为膜性肾病的一种有前景的治疗方法。
Indian J Nephrol. 2025 May-Jun;35(3):322-323. doi: 10.25259/IJN_391_2024. Epub 2024 Oct 10.
6
Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy.奥妥珠单抗对利妥昔单抗难治性磷脂酶A2受体相关膜性肾病的治疗有效。
Clin Kidney J. 2025 May 1;18(5):sfaf026. doi: 10.1093/ckj/sfaf026. eCollection 2025 May.
7
Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy.针对利妥昔单抗耐药的膜性肾病患者的新型B细胞和浆细胞靶向治疗方法。
Clin Kidney J. 2025 Mar 21;18(5):sfaf088. doi: 10.1093/ckj/sfaf088. eCollection 2025 May.
8
Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A receptor antibody: case reports.奥妥珠单抗治疗磷脂酶A受体抗体阳性和阴性患者的膜性肾病：病例报告
Front Immunol. 2025 Apr 15;16:1561638. doi: 10.3389/fimmu.2025.1561638. eCollection 2025.
9
Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights.泰它西普与他克莫司联合治疗难治性原发性膜性肾病：病例分析
Am J Case Rep. 2025 Apr 23;26:e946727. doi: 10.12659/AJCR.946727.
10
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.奥妥珠单抗和奥法木单抗在治疗伴有抗利妥昔单抗抗体的膜性肾病患者方面比利妥昔单抗更有效。
Kidney Int Rep. 2024 Dec 17;10(3):753-761. doi: 10.1016/j.ekir.2024.12.012. eCollection 2025 Mar.
利妥昔单抗或环孢素治疗膜性肾病。
N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427.
4
Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.奥滨尤妥珠单抗（一种用于肾移植候选者脱敏的 2 型抗 CD20 单克隆抗体）的安全性、药代动力学和药效学活性。
Am J Transplant. 2019 Nov;19(11):3035-3045. doi: 10.1111/ajt.15514. Epub 2019 Jul 23.
5
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.奥滨尤妥珠单抗联合苯丁酸氮芥治疗伴有合并症的 CLL 患者。
N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.
6
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.比较抗 CD20 抗体利妥昔单抗和 GA101 对慢性淋巴细胞白血病细胞的体外作用。
Br J Haematol. 2011 Feb;152(3):295-306. doi: 10.1111/j.1365-2141.2010.08428.x. Epub 2010 Dec 13.
7
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.通过工程改造新型 II 型抗 CD20 抗体，增强直接和免疫效应细胞介导的 B 细胞细胞毒性，提高 CD20 抗体治疗的疗效。
Blood. 2010 Jun 3;115(22):4393-402. doi: 10.1182/blood-2009-06-225979. Epub 2010 Mar 1.
8
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.M型磷脂酶A2受体作为特发性膜性肾病的靶抗原
N Engl J Med. 2009 Jul 2;361(1):11-21. doi: 10.1056/NEJMoa0810457.
9
Prognosis of untreated patients with idiopathic membranous nephropathy.未经治疗的特发性膜性肾病患者的预后。
N Engl J Med. 1993 Jul 8;329(2):85-9. doi: 10.1056/NEJM199307083290203.